Erlotinib in non-small cell lung cancer: A review

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 6, 2005, Pages 995-1002

  Blackhall, Fiona H ^a   Rehman, Shazza ^a   Thatcher, Nicholas ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Erlotinib; Non small cell lung cancer

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BILIRUBIN; CANERTINIB; CETUXIMAB; CISPLATIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; LOPERAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; NAVELBINE; PELITINIB; PLACEBO; PLATINUM DERIVATIVE; PROTEIN KINASE B; STAT3 PROTEIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VANDETANIB; Z 1839;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CIGARETTE SMOKING; CLINICAL TRIAL; CORNEA DISEASE; COUGHING; DIARRHEA; DISEASE COURSE; DOG; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; INHIBITION KINETICS; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; META ANALYSIS; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PATIENT CARE; PREDICTION; PROTEINURIA; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; SYMPTOM; SYSTEMATIC REVIEW; TIME; TREATMENT OUTCOME;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUINAZOLINES;

EID: 21744432350     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.6.995     Document Type: Review

References (38)

1. SCHOTTENFELD D: Etiology and epidemiology of lung cancer. In: Lung Cancer: principles and practice, 2nd edition. Pass HI, Mitchell JB, Johnson, DH, Turrisi AT, Minna JD (Eds), Philadelphia, Lippincott Williams and Wilkins (2000):367-397.
2. BUNN PA: Chemotherapy for advanced non-small cell lung cancer: who, what, when, why? J. Clin. Oncol. (2002) 20:23s-33s.
3. HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22(9):1589-1597.
4. ROSELL R, FOSSELLA F, MILAS L: Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer (2002) 38:43-49.
5. MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy, Oncogene (2000) 19:6550-6565.
6. RANSON M: Epidermal growth factor receptor tyrosine kinase inhibitors. Br. J. Cancer (2004) 90(12):2250-2255.
7. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomised Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. (2003) 21:2237-2246.
8. KRIS MG, NATALE RB, HERBST RS et al.: Efficacy and safety of gefitinib (Iressa, ZD 1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer. JAMA (2003) 290:2149-2158.
9. ASTRAZENECA: Gefitinib (Iressa) lung cancer ISEL trial shows no overall survival advantage in a highly refractory population. Press release, 17th December, 2004.
10. SHEPHERD FA, PEREIRA J, CIULEANU TE et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy; A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial. J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(14S):7022.
11. BOS M, MENDELSOHN J, KIM YM, ALBANELL J, FRY DW, BASELGA J: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. (1997) 3(11):2099-2106.
12. MOYER JD, BARBACCI EG, IWATA KK et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57(21):4838-4848.
13. POLLACK VA, SAVAGE DM, BAKER DA et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumour effects in athymic mice. J. Pharmacol. Exp. Ther. (1999) 291:739-748.
14. GRUNWALD V, HIDALGO M: Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. (2003) 30:23-31.
15. PRODUCT INFORMATION: Tarceva(TM), erlotinib tablets. Genentech Incorporated, South San Francisco, CA, 2004.
16. PFIZER Inc: CP-358,774 Investigator Brochure 1999. Groton, CT March 1999.
17. HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279.
18. MALIK SN, SIU LL, ROWINSKY EK et al.: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin. Cancer Res. (2003) 9(7):2478-2486.
19. WOLF M, SWAISLAND H, AVERBUCH S: Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin. Cancer Res. (2004) 10(14):4607-13.
20. KARP DD, SILBERMAN SL, CSUDAE R et al.: Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor OSI-774 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (1999) 18:388 (Abstr. 686).
21. PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol. (2004) 22:3238-3247.
22. GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(14S):7010.
23. HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE - A Phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(14S):7011.
24. GIACCONE G, HERBST RS, MANEGOLD C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A Phase III trial-INTACT 1. J. Clin. Oncol. (2004) 22(5):777-784.
25. HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A Phase III trial-INTACT 2. J. Clin. Oncol. (2004) 22(5):785-794.
26. PEREZ-SOLER R: The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin. Cancer Res. (2004) 10:4238s-4240s.
27. ROSELL R, DANIEL C, RAMLAU R et al.: Randomized Phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) versus CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S):7012.
28. ADJEI AA: Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy. Drug Future (2001) 26(11):1087.
29. ISOMURA M, FUKUOKA M, SONE S et al.: Identification of single nucleotide polymorphisms (SNPs) associated with adverse effects (AEs) of gefitinib. Journal of Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):3020.
30. DANSON S, BLACKHALL F, HULSE P, RANSON M: Interstitial Lung Disease in Lung Cancer: Separating Disease Progression from Treatment Effects. Drug Saf. (2005) 28(2):1-13.
31. SANDLER AB, BLUMENSCHEIN GR, HENDERSON T et al.: Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(14S):2000.
32. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
33. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
34. PAO W, MILLER V, ZAKOWSKI M et al.: FGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. PNAS (2004) 101(36):13306-13311.
35. MILLER VA, HERBST R, PRAGER D et al.: Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. J. Clin. Oncol. (2004) ASCO Annual Meeting Proceedings (2004) (Post-Meeting Edition) 22(14S):7061.
36. PEREZ-SOLER R, PIPERDI B, HAIGENTZ M, LING Y H: Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines. J. Clin. Oncol. ASCO Annual Meeting Proceedings. (2004) (Post-Meeting Edition) 22(14S):7026.
37. SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. (2000) 18:2095-2103.
38. BASELGA J: The Science of EGFR inhibition: a roadmap to improved outcomes? Signal (2004) 5(3):4-8.